个性化的路径:通过肠-大脑轴解锁阿尔茨海默病
Matteo Ceccon1, Johan B Kantsjö1, Francesca Ronchi1
1Institute of Microbiology, Infectious Disease, and Immunology/Charité - Universitätsmedizin Berlin, Berlin, Germany.
Visceral medicine
|August 19, 2024
概括
微生物干预对阿尔茨海默氏症 (AD) 有希望,可能改善认知功能. 整合微生物组分析的个性化方法对于理解AD进展和开发有效治疗至关重要.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 阿尔茨海默病 (AD) 的特点是大脑蛋白质聚合物导致认知能力下降.
- 目前的AD疗法可以控制症状;急需改变疾病的治疗方法.
- 在阿尔茨海默病患者中观察到肠道微生物组合的变化,这表明肠-大脑轴链接.
研究的目的:
- 审查针对阿尔茨海默病的微生物干预措施.
- 探索便微生物群移植,益生菌和饮食的潜力.
- 强调个性化的方法来治疗和研究AD.
主要方法:
- 现有关于AD中微生物干预的研究的叙述性综述.
- 分析微生物群组成变化和对认知功能的影响.
- 讨论对微生物组,临床和生活方式数据的综合分析的需求.
主要成果:
- 微生物干预,如FMT,益生菌和饮食,可能会改变微生物群的组成.
- 一些研究表明,这些干预措施对认知功能的有益影响.
- 在AD中微生物干预的确切作用机制尚不清楚.
结论:
- 考虑个体代谢和微生物组特征的个性化治疗策略对于AD至关重要.
- 需要进一步的研究来了解微生物干预的机制.
- 将微生物群分析与临床和生活方式数据相结合,对于全面了解AD至关重要.
更多相关视频
07:29Real-time Analysis of Gut-brain Neural Communication: Cortex wide Calcium Dynamics in Response to Intestinal Glucose Stimulation
Published on: December 29, 2023
631
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171